source
- Merck's diabetic eye-disease drug hits primary goal but faces commercial doubtsMerck announced results from a pivotal trial of its ophthalmology candidate remigromig, aimed at treating diabetic macular edema. The study achieved its primary endpoint, demonstrating that remigr…
- Bausch + Lomb CEO Brent Saunders abruptly departs after failed multibillion-dollar saleBrent Saunders, known as a leading dealmaker and one of the highest-paid executives in biopharma, has left his role as chief executive of Bausch + Lomb. His departure ends a second stint as CEO of…